Jump to content

Annie Luetkemeyer

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Ira Leviton (talk | contribs) at 00:51, 8 June 2020 (Copy editing, deletion of overlinks.). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Annie F. Luetkemeyer
Luetkemeyer speaks on HIV diagnosis for WorldMEDSchool in 2014
Born
Baltimore, Maryland U.S.
NationalityAmerican
EducationUniversity of California, San Francisco
Harvard University
OccupationInfectious diseases researcher
Years active1999-present

Annie F. Luetkemeyer is a Professor of Medicine and Infectious Diseases at the University of California, San Francisco. She specialises in infectious diseases, in particular tuberculosis, HIV and viral hepatitis.[1] During the COVID-19 pandemic Luetkemeyer led a clinical trial into the use of remdesivir. She has also looked at treatment of COVID-19 as a co-infection with HIV.

Early life and education

Luetkemeyer was born in Baltimore, Maryland, to Suzanne Luetkemeyer (née Frey) and John Alexander Luetkemeyer Jr., a commercial real estate developer. She is the youngest of three sisters, one of whom is the actor, Julie Bowen. She grew up in Ruxton-Riderwood, Maryland.[2] In 1984, Luetkeymer graduated from the Calvert School.[3]

In 1994, Luetkemeyer received a AB in American Studies from Stanford University, where she graduated with distinction.[4] In 1999, Luetkemeyer received an M.D. in Medicine from Harvard Medical School.[5] In 2002 and 2003, she trained in internal medicine at the University of California, San Francisco. In 2006, Luetkemeyer completed advance training in clinical research, also at the University of California, San Francisco, and then completed an infectious disease fellowship in 2007.[5]

Career

In 2012 Luetkemeyer called for investigations into the doses of medications used for the treatment of HIV infection and tuberculosis.[6] The recommendations had been re-written by the Food and Drug Administration in 2012. In a series of small studies in Europe it had been shown that rifampicin, a drug used to treat tuberculosis, could limit the effectiveness of efavirenz, a drug used to treat HIV. The drugs interact through a liver enzyme (cytochrome P450), which is produced at elevated levels in patients who take rifampicin, and breaks down the efavirenz. To overcome this, the 2012 Food and Drug Administration recommendations proposed larger doses of efavirenz. Luetkemeyer argued that the recommendations were not appropriate for all populations in the United States, and may result in more drug toxicity.[6] She showed that increasing the dosage of efavirenz may result in most side effects – as well as coming at a greater financial cost.[6]

During the COVID-19 pandemic, Luetkemeyer led investigations into potential therapies for coronavirus disease.[7][8] She is a member of the University of California, San Francisco cross-campus coronavirus disease task force.[9] In line with most official advice, Luetkemeyer called for older people and tose with pre-existing conditions to be more careful during the outbreak, as the virus "taxes all organ systems".[10] Luetkemeyer studied which coronavirus disease patients were most likely to benefit from treatment, when during their illness was most beneficial for treatment to occur and which types of treatment (antivirals or anti-inflammatories) were most appropriate. As well as studying researching potential treatment pathways, she has outlined what pre- and post exposure prophylaxis healthcare workers and household contacts can practise to prevent disease spread. In an effort to dispel any misinformation, Luetkemeyer has called for more randomized controlled trials to assess the impact of hydroxychloroquine, particularly as it can cause harmful side effects.[11] She is leading a clinical trial into the use of the drug remdesivir.[12][13] The San Francisco General Hospital SARS-CoV-2 guidelines only recommend treatment if patients are hospitalised or have strong risk factors for progression into severe disease. As of March 2020, the guidelines included remdesivir, or hydroxychloroquine if remdesivir was not feasible.

Selected works and publications

Scholia has an author profile for Annie Luetkemeyer.

References

  1. ^ Luetkemeyer, Annie (2 August 2016). "Hepatitis C is Curable". KQED.
  2. ^ Marbella, Jean (12 September 2010). "Julie Bowen's modern life". The Baltimore Sun.
  3. ^ "The Illustrious Luetkemeyer Girls". Reflections 2012. XIX (1). Calvert School: 16–19. Fall 2012.
  4. ^ "Anne F. Luetkemeyer, MD". IAS-USA. Retrieved 2020-04-15.
  5. ^ a b "Annie Luetkemeyer | UCSF Profiles". profiles.ucsf.edu. Retrieved 2020-04-15.
  6. ^ a b c Bardi, Jason (23 July 2012). "UCSF/SFGH Researchers Call for Change in New FDA Recommendation on HIV and TB Drug Doses". University of California, San Francisco.
  7. ^ Wachter, Robert; Luetkemeyer, Annie (15 March 2020). "Treatment options for COVID-19: Dr. Annie Luetkemeyer". The Hospitalist.
  8. ^ KupferschmidtApr. 7, Kai; 2020; Pm, 3:50 (2020-04-07). "Trials of drugs to prevent coronavirus infection begin in health care workers". Science | AAAS. Retrieved 2020-04-15. {{cite web}}: |last2= has numeric name (help)CS1 maint: numeric names: authors list (link)
  9. ^ "About the Cross-campus Infectious Disease COVID-19 Task Force | HIV, ID and Global Medicine". hividgm.ucsf.edu. Retrieved 2020-04-20.
  10. ^ Hafner, Katie (14 March 2020). "How to Protect Older People From the Coronavirus". The New York Times.
  11. ^ @NatGeoUK (2020-03-25). "What scientists do and don't know about treating coronavirus". National Geographic. Retrieved 2020-04-15.
  12. ^ "UCSF's noon grand rounds: A slow reopening, racial disparities and no quick remedies". Mission Local. 2020-04-17. Retrieved 2020-04-19.
  13. ^ "Anti-viral Remdesivir, Wall Street's darling, may not even work against COVID-19". Mission Local. 2020-04-18. Retrieved 2020-04-19.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Annie_Luetkemeyer&oldid=961357918"